Michael Andreeff

Michael Andreeff is a Professor of Medicine and holds the Paul and Mary Haas Chair in Genetics at The University of Texas MD Anderson Cancer Center. His research focuses on leukemia biology, TP53 mutations, and apoptosis resistance in hematological malignancies. Recent work includes restoring wild-type p53 conformation in TP53-Y220C-mutant AML, targeting FLT3-ITD and MDM2 pathways, and engineering iPSC-derived mesenchymal stromal cells to modulate tumor microenvironments. He has published in Blood, Cancer Research, and Clinical Cancer Research, and leads clinical trials integrating FLAG-based therapy and novel oral combinations for AML.